ZaBeCor gets green flag from FDA for asthma drug trials

NEW YORK The Food and Drug Administration has given biotech ZaBeCor Pharmaceuticals permission to begin clinical trials of a drug for treating asthma.

The company plans to begin phase 1 testing of the drug Excellair, which targets proteins involved with inflammatory diseases such as asthma.

The drug is based on research from the University of Pennsylvania School of Medicine.